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Abstract
Aims: To verify the effects of several 5,8-dimethoxy-1,4-naphthoquinone
(DMNQ) derivatives on LPS-induced NO production, cellular ROS levels and
cytokine expression in BV-2 microglial cells.
Main methods: An MTT assay and FACS flow cytometry were performed to
assess the cellular viability and apoptosis and cellular ROS levels, respectively. To
examine the expression of pro-inflammatory cytokines and cellular signaling
pathways, semi-quantitative RT-PCR and Western blotting were also used in this
study.
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Key findings: Among the six newly synthesized DMNQ derivatives, 2-
cyclohexylamino-5,8-dimethoxy-1,4-naphthoquinone (R6) significantly inhibited
the NO production, cellular ROS levels and the cytokines expression in BV-2
microglial cells, which stimulated by LPS. Signaling study showed that compound
R6 treatment also significantly down-regulated the LPS-induced phosphorylation
of MAPKs (ERK, JNK and p38) and decreased the degradation of IκB-α in BV2
microglial cells.
Significance: Our findings demonstrate that our newly synthesized compound
derived from DMNQ, 2-cyclohexylamino-5,8-dimethoxy-1,4-naphthoquinone
(R6), might be a therapeutic agent for the treatment of glia-mediated
neuroinflammatory diseases.
Keywords: Neuroscience, Immunology, Cell biology, Medicine, Biochemistry
1. Introduction
Inflammation plays an important role in the pathology of neurodegenerative
disorders in the brain. Microglia are glial cells that function as the prime effector
cells in immune defense and inflammatory responses in the central nervous system
(CNS) [1, 2, 3]. Increased evidences showed, activated microglia was involved in
pathological processes for diseases such as Alzheimer’s disease [4], Parkinson’s
disease [5], and multiple sclerosis [6], through producing the cytokines and
superoxides. In response to pro-inflammatory triggers, microglia exhibited active
phenotype, resulting in a shift of cellular function and subsequent release of
cytotoxic factors (e.g., tumor necrosis factor-alpha [TNF-α], nitric oxide [NO], and
reactive oxygen species [ROS]) aimed at destroying the invading pathogens. All of
these evidences suggest that microglia can become a major source of cytokines and
ROS production to drive progressive neuronal damages, and these damages are
implicated in the chronic nature of neurodegenerative diseases.
In response to environmental changes, such as neuronal damage, microglial cells
proliferate and become phagocytic, and up-regulate the expression of various
molecules (cytokines, adhesion molecules, and transcription factors) [7, 8, 9, 10].
Inflammatory agonists, such as bacterial lipopolysaccharides (LPS), the β-amyloid-
related peptides, and human immunodeficiency virus (HIV) coat protein gp120,
could induce the microglial cells activation by producing many inflammatory
factors, such as TNF-α, interleukin-1betaβ (IL-1β) and NO, which involves in glia-
mediated neurotoxicity [11, 12].
Thus, finding new compounds to control the activity of microglial cells may be
critical to limiting glia-mediated neurotoxicity and its consequences and delaying
the progression of neurodegenerative diseases and neuroinflammation in the CNS.
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Naphthoquinones are widely distributed in nature and play important physiological
roles in animals and plants. Their derivatives have exhibited a variety of biological
responses, which include anti-allergic, anti-bacterial, anti-fungal, anti-inflammato-
ry, anti-thrombotic, anti-platelet, anti-viral, apoptosis, lipoxygenase, radical
scavenging, and anti-ringworm activities [13, 14]. As a consequence, the molecular
framework of many pharmaceuticals and biologically important compounds
contain a quinine moiety. The 5,8-dimethoxy-1,4-naphthoquinone (DMNQ) used
as common start compound to synthesize Naphthoquinone derivatives, and it was
reported that DMNQ derivatives exhibit the anti-tumor activity in breast cancers
[15, 16], and could also prevent cell proliferations through regulating the cellular
MAPK and PI3 K signaling pathways [17, 18]. But the inhibitory effect of
naphthoquinone derivatives on the LPS-induced activation of microglial cells is not
yet understood.
In the present studies, we investigated the potency of serial derivatives synthesized
from DMNQ as inhibitors of BV2 microglia activation by probing NO production,
the expression of cytokines (e.g., IL-6, TNF-α and IL-1β), and cellular ROS levels
and their mechanism of action including MAPK and NF-kB signaling pathways.
2. Materials and methods
2.1. Reagents
Lipopolysaccharides (LPS, from Escherichia coli serotype 0111:B4) were
purchased from Sigma (St. Louis, MO, USA), and the iNOS inhibitor S-
methylisothiourea sulfate (SMT) was obtained from Calbiochem (San Diego, CA,
USA). A classical Michael addition reaction was used to synthesize 5,8-
dimethoxy-1,4-naphthoquinone (DMNQ) derivatives.
2.2. Synthesis of 5,8-dimethoxy-1,4-naphthoquinone (DMNQ)
derivatives
The synthetic schemes for 2-substituted amino-DMNQ derivatives are summarized
in Suppl. 1. The starting material was 5-dihydroxynaphthalene (Fig. 1A), and it
was reacted with sodium hydroxide and dimethyl sulfate under nitrogen to produce
5,8-dimethoxynaphthalene (Fig. 1B). This compound was then brominated with N-
bromosuccinimide (NBS) at room temperature for 3 h to yield 1,5-dibromo-4,8-
dimethoxynaphthalene (Fig. 1C). After methoxylation with sodium methoxide and
copper (I) iodide in a N,N-dimethyl formamide/methanol solution, oxidative
demethylation of the 1,4,5,8-tetramethoxynaphthalene (Fig. 1D) was performed
with cerium (IV) ammonium nitrate (CAN) to produce the key intermediate,
DMNQ (Fig. 1E). The direct 1,4- addition of various alkylamines to the quinone
moiety of DMNQ (Fig. 1F) synthesized the appropriated 2-alkylamino-DMNQs,
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with yields varying from 23.6 to 55.5%. The compounds used in this study are
marked as R1 to R6, and their full names are summarized in Table 1.
2.3. Cell culture
BV2 microglial cells were cultured in Dulbucco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT,
USA) and penicillin-streptomycin (100 U/ml, 100 μg/ml). The BV2 microglial
cells were pre-treated with 30 μM of the DMNQ derivatives, followed by treatment
with 1 μg/mL of LPS.
2.4. Cell viability assay
Cell viability was quantitatively determined using a 3-[4][4,5-dimethylthiazol-2-
yl]-2, 5-diphenyltetrazolium bromide (MTT) colorimetric assay. Briefly, BV2
microglial cells were grown in 96-multi-well plates in DMEM in the presence of
only the R6 compound at the indicated concentration ranges (0 μM to 30 μM) for
24 h. The produced formazan was quantified by measuring the absorbance of the
[(Fig._1)TD$FIG]
Fig. 1. Simplified diagram for synthesis of the DMNQ derivatives.
Table 1. The full name of DMNQ derivatives used in the experiments.
R No Full Name
Propene- R1 2-Vinylamino-5,8-dimethoxy-1,4-naphthoquinone
i-propyl- R2 2-i-Propylamino-5,8-dimethoxy-1,4-naphthoquinone
Cyclopropyl- R3 2-Cylopropylamino-5,8dimethoxy-1,4-naphthoquinone
i-Butyl- R4 2-i-Butylamino-5,8-dimethoxy-1,4-naphthoquinone
l-methylpropyl- R5 2-(1-Methylpropylamino-5,8-dimethoxy-1,4-naphthoquinone
Cyclohexyl- R6 2-cyclohexylamino-5,8-dimethoxy-1,4-naphthoquinone
R: substituent group; No: Number.
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dye solution at 490 nm using a microtiter plate reader (Molecular Devices, Menlo
Park, CA).
2.5. Biochemical assay for the production of NO
NO production was assessed based on the accumulation of nitrite in the medium
using a colorimetric reaction with Griess reagent (0.1% N-[1][1-naphthyl]
ethylenediamine dihydrochloride, 0.1% sulfanilamide, and 2.5% H3PO4). Briefly,
the culture supernatants were collected and mixed with an equal volume of Griess
reagent for 10 min and by measuring absorbance at 540 nm with a UV MAX
kinetic microtiter plate reader.
2.6. Western blotting analysis
Protein lysates (30 μg) were separated on 12% sodium dodecyl sulfate-
polyacrylamide gels and transferred onto nitrocellulose membranes (Millipore,
Bedford, MA, USA). The membranes were blotted with antibodies against IκB-α
(Santa Cruz Biotechnology, USA), iNOS (Upstate Biotech, Charlottesville, VA,
USA), pERK, pJNK (Santa Cruz Biotechnology, USA), and NAPDH (Sigma, St.
Louis, MO, USA) at 4 °C overnight and then incubated with horseradish
peroxidase-conjugated goat anti-rabbit IgG (Sigma) or anti-mouse IgG (Sigma) for
1 h at room temperature (RT). The specific binding was detected using a
chemiluminescence detection system (Amersham, Berkshire, UK) according to the
manufacturer's instructions.
2.7. RNA isolation and semi-quantitative RT-PCR analysis
To isolate the total RNA, the cells were lysed with Trizol (Invitrogen). After
chloroform was added at 1/5 volume of Trizol used, the cell lysates were mixed
thoroughly by vortexing and centrifuged at 15,000 g for 15 min at 4 °C. Upper
phase solution was harvested and mixed by equal volume of isopropanol. After
centrifugation at 12,000 g for 8 min at RT, the precipitated RNA was washed with
75% EtOH and melted with DDW. The first-strand cDNA was synthesized from
0.5 μg of DNase-treated total RNA using 0.5 μg random hexamers (Invitrogen),
and 200 U Moloney murine leukemia virus reverse transcriptase (Invitrogen) in a
volume of 20 μl at 37 °C for 60 min. The first strand cDNA (1 μl) was used for
PCR amplification in a 25 μl reaction mixture. PCR was performed under the
following conditions: 94 °C for 30 sec, 55–60 °C for 30 sec, and 72 °C for 30 sec,
with additional incubation for 10 min at 72 °C after cycle completion. Primers for
iNOS forward:5'-CCC TTC CGA AGT TTC TGG CAG CAG C-3'; reverse:5'-
GGC TGT CAG AGC CTC GTG GCT TTG G −3'; for IL-1β forward 5'-ATG
GCA ACT GTT CCT GAA CTC AAC T-3'; reverse 5'-CAG GAC AGG TAT
AGA TTC TTT CCT TT-3'; for TNF-α forward 5'-CTC AAA TGG GCT TTC
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CGA ATT-3'; reverse 5'-TCC AGC CTC ATT CTG AGA CAG A-3'; for IL-6
forward 5'-AGA AGG AGT GGC TAA GGA CCA A-3'; reverse 5'-AAC GCA
CTA GGT TTG CCG AGT A-3'; for GAPDH Forward 5'-TTC ACC ACC ATG
GAG AAG GC-3'; Reverse: 5'-GGC ATG GAC TGT GGT CAT GA-3'. The
amplified DNA fragments were quantified by densitometry using the MULTI-
ANALYST program of Model GS-700 Imaging Densitometer (Bio-Rad, Hercules,
CA, USA).
2.8. Measurement of ROS by flow cytometry
BV-2 cells were incubated with 10 mM CM-H2DCFDA (Invitrogen), a
fluorescence-based ROS indicator, at 37 °C for 15 min at the end of the different
treatments. The DCF fluorescence intensities of 10,000 cells were analyzed by
FACScan (BD FACSCalibur).
2.9. Statistical analysis
Data are expressed as mean ± SD. Differences between groups were tested for
statistical significance using the Student’s t test, and p values of < 0.05 were
considered significant.
3. Results
3.1. Compound R6 inhibits NO production in BV2 microglial
cells
To examine the inhibitory effects of the DMNQ derivatives on the NO production
of BV2 microglia, the BV2 cells were pre-treated with 30 μM of the compounds
for 30 min and were then treated with LPS (1 μg/ml) for 24 h. As shown in Fig. 2,
the compounds R1, R2, R4, R5 and R6 significantly inhibited the production of
NO, whereas compound R3 had no inhibitory effect. Moreover, compound R6
exhibited a greater inhibitory effect on the LPS-induced production of NO than the
other compounds. Thus, our following research focused on the functional studies of
compound R6. To investigate whether compound R6 could affect the cell viability,
BV-2 microglial cells were treated with compound R6 without LPS stimulation,
and the cell viability was measured by an MTT assay (Fig. 3). The results showed
that compound R6 did not affect the cell viability.
3.2 Compound R6 inhibits LPS-induced NO production and iNOS expression
in BV2 microglial cells
To examine the concentration dependence and time course of the inhibitory activity
of compound R6 on NO production and the iNOS protein expression, the BV-2
microglial cells were pre-treated with compound R6 at various concentrations and
then subsequently treated with LPS (1 μg/ml) for 24 h. As shown in Fig. 4 (A and
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C), that compound R6 dose-dependently inhibited the LPS-induced NO production
(approximately 35% at 30 μM) and iNOS expression (almost basal levels at 30
μM). Followed experiments were performed to understand of the inhibitory effect
of compound R6 on NO secretion. The BV-2 microglial cells were pre-treated with
compound R6 (30 μM), followed by LPS (1 μg/ml) stimulation for indicated times.
As shown in Fig. 4 (B and D), that compound R6 time-dependently inhibited NO
production and iNOS expression. To evaluate the inhibitory efficiency of
compound R6 on the LPS-induced NO production, we compared its inhibitory
[(Fig._2)TD$FIG]
Fig. 2. New compounds inhibit the LPS-induced production of NO in BV2 microglial cells. BV2
microglial cells were pre-treated with the indicated compounds for 30 min followed by treatment with
LPS (1 μg/mL) for 24 h. Then, the NO production was analyzed in the medium using Griess reagent.
Three independent replicates were performed for all the experiments. The data are presented as the
mean ± SD. *p ≤ 0.05; ** p ≤ 0.01, *** p ≤ 0.001.
[(Fig._3)TD$FIG]
Fig. 3. Effect of compound R6 on cell viabilities. The BV2 microglial cells were treated with
compound R6 at different concentrations for 24 h without LPS treatment. Cell viabilities were probed
using an MTT assay. Three independent replicates were performed for all the experiments. The data are
presented as the mean ± SD. *p ≤ 0.05; ** p ≤ 0.01, *** p ≤ 0.001.
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[(Fig._4)TD$FIG]
Fig. 4. Compound R6 inhibits the LPS-induced production of NO and expression of iNOS in BV2 microglial cells. BV-2 microglial cells were pre-treated with
various concentrations of compound R6 (1 μM, 10 μM, 20 μM and 30 μM) for 30 min, followed by LPS (1 μg/mL) stimulation for 24 h, and the NO production (A)
and iNOS expression (C) were detected using Griess reagent and Western blotting, respectively. BV-2 microglial cells were pre-treated with compound R6 (30 μM)
for 30 min, followed by LPS (1 μg/mL) stimulation for the indicated times. NO production (B) was detected in the medium using Griess reagent, and the cellular
iNOS expression was examined by Western blotting (D). BV-2 microglial cells were pre-treated with compound R6 (30 μM) and SMT (a selective inhibitor of iNOS,
1 mM) for 30 min, followed by LPS (1 μg/mL) stimulation for the indicated times. NO production (E) was detected in the medium using Griess reagent, and the
cellular iNOS expression was examined by Western blotting (F). Three independent replicates were performed for all the experiments. The data are presented as the
mean ± SD. *p ≤ 0.05; ** p ≤ 0.01, *** p ≤ 0.001. Full, unmodified images of this figure are available as Supplementary Material. Article
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activity with SMT, a selective inhibitor of iNOS (Figs. 4 E and F). The results
showed that compound R6 inhibitory efficiency on LPS-induced microglial NO
production and iNOS expression were similar to that of SMT, suggesting that
compound R6 may be a good inhibitor candidate for NO production.
3.3 Compound R6 decreases LPS-induced cellular ROS levels and the
expression of cytokines in BV2 microglial cells
LPS stimulation triggers the production of inflammatory mediators, the
expression of cytokines and an increase in cellular ROS levels. To investigate
the effect of compound R6 on the LPS-induced microglial ROS levels and the
expression of pro-inflammatory cytokines, BV-2 microglial cells were pre-treated
with compound R6 for 30 min, followed by LPS (1 μg/ml) stimulation for the
indicated times. As shown in Fig. 5C, the LPS-induced mRNA expression of pro-
inflammatory cytokines, such as TNF-α, iNOS, IL-6 and IL-1β, and the cellular
ROS levels were significantly down-regulated by treatment with compound R6
(Figs. 5 A and B).
[(Fig._5)TD$FIG]
Fig. 5. Compound R6 decreases LPS-induced cellular ROS levels and the expression of cytokines in
BV2 microglial cells. BV-2 microglial cells were pre-treated with compound R6 (30 μM) for 30 min,
followed by LPS stimulation. Then, the intracellular ROS levels were analyzed by FACS. (A) The
increased fold of ROS levels are presented by the mean ± SD (n = 3). (B) The mRNA expression of
iNOS, TNF-α, IL-6 and IL-1β were examined by semi-quantitative RT-PCR (C). Three independent
replicates were performed for all the experiments. **p < 0.01, ***p < 0.001. Full, unmodified images
of this figure are available as Supplementary Material.
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3.4 Compound R6 down-regulates the LPS-induced phosphorylation of
MAPKs and IκB-α degradation
To understand the mechanism of action for the inhibition of the LPS-induced NO
production and the expression of cytokines by compound R6, we examined the
effect of compound R6 on the phosphorylation of MAPKs (JNK, p38, ERK,) and
IκB-α degradation stimulated by LPS. BV2 microglial cells were pre-treated with
30 μM of compound R6 for 30 min, followed by LPS (1 μg/ml) treatments for
indicated times. As shown in Fig. 6, that compound R6 significantly down-
regulated the LPS-induced phosphorylation of MAPKs (JNK, ERK and p38)
(Figs. 6 A–C) as well as IκB-α degradation (Fig. 6 D).
[(Fig._6)TD$FIG]
Fig. 6. Compound R6 down-regulates the phosphorylation of MAPKs and IκB-α degradation. BV2
microglial cells were pre-treated with compound R6 (30 μM) for 30 min, followed by LPS (1 μg/ml)
treatment for the indicated times. The Western blot was performed to examine the phosphorylation
levels for the MAPKs, including ERK (A), JNK (B) and p38 (C). The effect of compound R6 on the
NF-κB pathway was also examined by detecting the degradation of IκB-α (D). Three independent
replicates were performed for all the experiments. Full, unmodified images of this figure are available as
Supplementary Material.
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4. Discussion
Microglia play a crucial roles in neurodegenerative disease by either single or
chronic exposure to environmental toxins, neuronal damage, cytokines, and disease
proteins [19]. Increasing evidence has shown that many inflammatory mediators,
such as TNF-α, IL-1β, and IL-6, have been found in the striatum in human
Parkinson’s Disease (PD) and Alzheimer’s Disease (AD) postmortem brains [20,
21, 22, 23], and an up-regulation of iNOS and cyclooxygenase 2 in amoeboid
microglia are located in the substantia nigra of PD patients [24]. Thus, controlling
the activation of the brain microglia may be an important approach to delay the
progress of neuron degenerative diseases.
1,4-naphthoquinone derivatives have powerful pharmacological effects of
antimicrobial and antitumor activities [25, 26], and these derivatives may be toxic
to cells through a number of mechanisms, including intercalation, arylation, redox
cycling, induction DNA strand breaks, and the generation of free radicals [27]. In
this study, we examined the effect of six newly synthesized DMNQ derivatives on
the LPS-induced production of NO in BV2 microglial cells. The results showed
that among the six newly synthesized DMNQ derivatives, compound R6 exhibited
the good inhibitory effect on the LPS-induced production of NO in BV2 microglial
cells (Fig. 2) and did not affect the cell viability (Fig. 3). When examining the
dose- and time-dependent inhibitory effect of compound R6 on the LPS-induced
production of NO in BV2 microglial and the expression of iNOS protein (Figs. 4
A–D), it was found that compound R6 exhibited a significant inhibitory effect on
NO production through decreasing the expression of the iNOS protein in BV2
microglial cells.
LPS stimulation triggers diverse microglial responses, including phagocytosis,
ROS production, and inflammatory mediator production through MAPKs signaling
cascades in microglial cells [28, 29]. ROS play a essential role in microglial
activation and in the progression of neurodegenerative diseases, such as
Alzhiemer’s disease and Parkinson's disease [30]. Compound R6 significantly
attenuated cellular ROS levels stimulated by LPS in BV2 microglial cells (Fig. 5 A
and B). Furthermore, LPS stimulation could also increase the expression of
cytokines in microglial cells [25, 26]. Thus, the effects of compound R6 on the
LPS-induced gene expression of cytokines were also determined (Fig. 5C). The
results showed that compound R6 significantly inhibited the mRNA expression of
iNOS, TNF-α, IL-6 and IL-1β, suggesting that compound R6 has a potency to
inhibit the LPS-induced activation of BV2 microglial cells. All these phenomena
suggest that ROS-dependent signaling pathways are most likely responsible for the
inhibitory effects described above.
MAPK family plays crucial roles in the LPS-induced pro-inflammatory products
and neuroinflammation [31, 32, 33]. It was reported that DMNQ derivatives
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exhibit anti-tumor activity by inducing apoptosis via caspases and mitogen
activated protein (MAP) kinase-dependent pathways [34, 35, 36]. Our previous
study showed that JNK signaling plays a important role in the regulation of the
LPS-stimulated production of NO and the expression of iNOS, and the regulatory
effect of the JNK signaling pathway on NO production was dependent on cellular
ROS [37]. Additionally, increasing evidence suggests that the ROS-dependent NF-
κB signaling pathway also participates in the LPS-induced expression of cytokines
and activation of microglial cells [38, 39, 40, 41, 42, 43]. Our results showed that
treatment with compound R6 significantly down-regulated the LPS-induced
phosphorylation of MAPKs (ERK, JNK and p38) and the degradation of IκB-α
(NF-κB inhibitor) (Fig. 6) in an early time course, suggesting that compound R6
exhibits its inhibitory effect on the LPS-induced activation of BV2 microglial cells
through blocking the primary signaling pathways that are ROS-dependent.
5. Conclusion
Taken together, our results showed that compound R6, synthesized from DMNQ,
significantly inhibited NO production, the expression of cytokines and decreased
the cellular ROS levels in LPS-stimulated BV-2 microglial cells by down-
regulating the ROS-dependent MAPK/NF-κB signaling pathways. Our findings
provide a new approach to therapeutic targets for glia-mediated neuroinflammatory
diseases.
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